Examining Advances in Ovarian Cancer and Strategies to Promote Optimal and Equitable Care

In this online program, experts discuss key advances and equitable care delivery for patients with ovarian cancer. Watch an on-demand webcast from the live meeting featuring the perspectives of clinical pharmacy and managed care specialists, download the corresponding slides, and read ClinicalThought commentary on key highlights and frequently asked questions from the live webinar.

Share

Program Content

Activities

Equitable Care in OC
Examining Advances in Ovarian Cancer and Strategies to Promote Optimal and Equitable Care
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 08, 2023

View Activity

Activities

FAQs: Equitable Care in OC
FAQs: Advances and Equitable Care in Ovarian Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: April 11, 2023

View Activity
PARPi Indications in OC
Current PARP Inhibitor Indications for Advanced Ovarian Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: February 02, 2024

View Activity

Activities

Advances and Equitable Care in OC: On Demand
Examining Advances in Ovarian Cancer and Strategies to Promote Optimal and Equitable Care
Video
Congratulations: You achieved a completion on 04/09/2022

Released: April 24, 2023

Expires: April 23, 2024

View Activity

Faculty

cover img faculity

Laura R. Bobolts, PharmD, BCOP

SVP, Clinical Strategy and Growth
OncoHealth
Plantation, Florida

cover img faculity

Colleen Bohnenkamp, PharmD, BCOP, BCPS

Oncology Clinical Pharmacist
The University of Kansas Health System
Kansas City, Kansas

Provided by

ProCE Banner

Provided by ProCE, LLC, in partnership with Clinical Care Options, LLC

Supporters

Supported by educational grants from AstraZeneca, GSK, ImmunoGen, Inc., Merck Sharp & Dohme LLC, and Novocure, Inc.

AstraZeneca

GSK

ImmunoGen, Inc.

Merck Sharp & Dohme, LLC

Novocure, Inc

Partners

Clinical Care Options, LLC

ProCE Banner